Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$13.00 +2.9%	$11.42	$3.98 ▼ $13.40	$1.98B	1.92	2.17 million shs	1.95 million shs
IMCR Immunocore	$32.93 +0.8%	$33.30	$23.15 ▼ $39.33	$1.66B	0.77	328,243 shs	289,496 shs
PVLA Palvella Therapeutics	$53.42 +4.1%	$32.98	$11.17 ▼ $53.93	$590.83M	-0.01	156,619 shs	161,988 shs
TARS Tarsus Pharmaceuticals	$57.25 +1.2%	$43.84	$25.19 ▼ $57.60	$2.42B	0.79	729,781 shs	615,773 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	-0.31%	+21.95%	+45.58%	+182.00%
IMCR Immunocore	0.00%	+0.15%	-6.63%	+5.68%	-9.89%
PVLA Palvella Therapeutics	0.00%	+12.94%	+38.29%	+125.21%	+5,341,999,900.00%
TARS Tarsus Pharmaceuticals	0.00%	+5.61%	+34.90%	+33.20%	+119.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.4049 of 5 stars	1.4	1.0	4.2	2.0	1.7	0.6
IMCR Immunocore	1.7738 of 5 stars	3.3	1.0	0.0	2.3	2.5	0.0
PVLA Palvella Therapeutics	1.9731 of 5 stars	2.5	0.0	0.0	3.2	2.5	0.6
TARS Tarsus Pharmaceuticals	1.9052 of 5 stars	2.5	1.0	0.0	3.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-4.81% Downside
IMCR Immunocore	2.50	Moderate Buy	$58.00	76.13% Upside
PVLA Palvella Therapeutics	3.09	Buy	$58.50	9.51% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	16.45% Upside

Current Analyst Ratings Breakdown

Latest PVLA, IMCR, TARS, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $66.00
8/15/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $75.00
8/15/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $60.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
8/5/2025	PVLA Palvella Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$54.00
8/4/2025	PVLA Palvella Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$90.00
7/21/2025	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$56.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	11.06	N/A	N/A	$1.18 per share	11.02
IMCR Immunocore	$310.20M	5.35	N/A	N/A	$7.71 per share	4.27
PVLA Palvella Therapeutics	$42.81M	13.80	N/A	N/A	$4.32 per share	12.37
TARS Tarsus Pharmaceuticals	$182.95M	13.21	N/A	N/A	$7.88 per share	7.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-62.30%	-43.34%	11/12/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.33	N/A	N/A	N/A	-31.13%	-32.36%	-21.04%	11/12/2025 (Estimated)

Latest PVLA, IMCR, TARS, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.78	-$0.86	-$0.08	-$0.86	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.33	-$0.48	-$0.15	-$0.48	$95.81 million	$102.66 million
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
IMCR Immunocore	1.01	5.89	5.86
PVLA Palvella Therapeutics	N/A	7.67	8.84
TARS Tarsus Pharmaceuticals	0.22	5.26	5.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
IMCR Immunocore	84.50%
PVLA Palvella Therapeutics	40.11%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
IMCR Immunocore	10.40%
PVLA Palvella Therapeutics	20.50%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
TARS Tarsus Pharmaceuticals	50	42.21 million	38.43 million	Optionable

PVLA, IMCR, TARS, and ADPT Headlines

Recent News About These Companies

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Aberdeen Group plc

August 24 at 4:07 AM | marketbeat.com

Nuveen LLC Purchases New Shares in Tarsus Pharmaceuticals, Inc. $TARS

August 24 at 3:41 AM | marketbeat.com

Vanguard Group Inc. Increases Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

August 24 at 3:18 AM | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Atika Capital Management LLC

August 23 at 7:48 AM | marketbeat.com

Russell Investments Group Ltd. Acquires 132,450 Shares of Tarsus Pharmaceuticals, Inc. $TARS

August 23 at 4:26 AM | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Invesco Ltd.

August 20, 2025 | marketbeat.com

Lord Abbett & CO. LLC Acquires 51,714 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 16, 2025 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 6,000 Shares of Stock

August 15, 2025 | marketbeat.com

Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.

August 15, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $300,000.00 in Stock

August 14, 2025 | insidertrades.com

Informed Momentum Co LLC Decreases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 14, 2025 | marketbeat.com

Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87

August 12, 2025 | msn.com

Blair William & Co. IL Sells 15,814 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 12, 2025 | marketbeat.com

Q3 EPS Forecast for Tarsus Pharmaceuticals Raised by Analyst

August 11, 2025 | marketbeat.com

Brokers Offer Predictions for TARS Q3 Earnings

August 11, 2025 | marketbeat.com

Analyst Estimates: Here's What Brokers Think Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Second-Quarter Report

August 9, 2025 | finance.yahoo.com

FY2027 Earnings Forecast for TARS Issued By HC Wainwright

August 9, 2025 | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 13.4% - What's Next?

August 8, 2025 | marketbeat.com

Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result

August 7, 2025 | finance.yahoo.com

Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum

August 7, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, IMCR, TARS, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$13.00 +0.37 (+2.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.86 -0.14 (-1.08%)

As of 08/22/2025 07:35 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Immunocore NASDAQ:IMCR

$32.93 +0.26 (+0.80%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$33.01 +0.08 (+0.23%)

As of 08/22/2025 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Palvella Therapeutics NASDAQ:PVLA

$53.42 +2.11 (+4.11%)

As of 08/22/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Tarsus Pharmaceuticals NASDAQ:TARS

$57.25 +0.69 (+1.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$58.04 +0.80 (+1.39%)

As of 08/22/2025 07:09 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time